Acesion Pharma Initiates Phase 2 Trial of First-in-Class SK Ion Channel Inhibitor AP31969 for Atrial Fibrillation
核心洞察
Acesion Pharma (搜索) has begun enrolling patients in a randomized, double-blind, placebo-controlled Phase 2 trial of AP31969, a novel oral SK ion channel (搜索) inhibitor for atrial fibrillation (搜索) rhythm control.
The study will recruit 200 patients across eight European countries and utilize implantable loop recorders for continuous cardiac monitoring to assess AF burden and proarrhythmia risk.
Phase 1 results in 92 healthy volunteers demonstrated favorable safety profile and suitable pharmacokinetics, with no clinically relevant QTc prolongation effects.
Acesion Pharma (搜索) has commenced patient enrollment in a Phase 2 clinical trial evaluating AP31969, a first-in-class oral SK ion channel (搜索) inhibitor designed for rhythm control in atrial fibrillation (搜索) (AF). The randomized, double-blind, placebo-controlled study represents a significant milestone for the biotech company as it advances its lead compound toward addressing critical safety limitations of existing antiarrhythmic therapies.
Trial Design and Endpoints
The Phase 2 study (NCT07267949) will recruit 200 patients across eight European countries, with completion anticipated in the first quarter of 2027. The trial's primary efficacy endpoint is AF burden, defined as the percentage of time a participant spends in atrial fibrillation (搜索). A key safety measure focuses on the occurrence of ventricular proarrhythmia (搜索), which represents a major limitation of currently available antiarrhythmic drugs.
To enable robust evaluation of these endpoints, all participants will receive an implantable loop recorder, allowing for continuous 24/7 cardiac rhythm monitoring. This approach provides precise measurement of AF burden efficacy while enabling comprehensive assessment of proarrhythmia risk.
Phase 1 Safety and Pharmacokinetic Results
Acesion successfully completed a Phase 1 clinical trial of AP31969 in 92 healthy volunteers in 2025 (NCT06066099). The study included single ascending dose (SAD) and multiple ascending dose (MAD) components, evaluating safety, pharmacokinetics, and effects on the QT interval (QTc). QTc prolongation serves as a well-established ECG marker of proarrhythmia risk.
According to the company, AP31969 demonstrated a favorable safety profile and pharmacokinetics suitable for chronic oral administration. Importantly, the trial showed that clinically relevant effects of AP31969 on QTc could be ruled out, supporting a favorable safety profile regarding proarrhythmia risk.
Clinical Significance and Market Potential
Anders Gaarsdal Holst, Chief Executive Officer of Acesion, emphasized the significance of advancing AP31969 into Phase 2 development. "With the use of implantable loop recorders in the trial, we can precisely estimate AF burden efficacy, as well as understand the risk of proarrhythmia," Holst stated.
He noted that the ability to robustly understand both efficacy and key safety parameters within a therapy class is unusual in a Phase 2 cardiovascular trial. "If successful, [this approach] will greatly de-risk Phase 3 development and accelerate AP31969's path to becoming the preferred treatment option for the increasing number of patients suffering from AF," Holst added.
Acesion projects that AP31969 has the potential to become a first-line therapy by addressing the proarrhythmia risks associated with current treatments. The company notes that the atrial fibrillation (搜索) population in the US and EU is projected to reach 25 million by 2030, highlighting the significant unmet medical need in this therapeutic area.